At Cayuga Biotech, we realize that accidents happen - we want you to live to tell the story

Trauma and hemorrhage are intertwined conditions that account for the number one cause of death and disability worldwide. The market for general trauma is essentially unmet by current technology.

 Increasing survival rates and minimizing disability from trauma requires new therapeutics

Cayuga Biotech is a startup company developing a commercially viable nanotherapeutic drug to treat both internal and external hemorrhage. 

We envision our product as a universal hemostat able to generate clots in all bleeding cases – compressible, non-compressible and internal injuries – while minimizing the risk of side effects.